FIELD: medicine.
SUBSTANCE: inventions relate to the field of immunology. Claimed are a single-chain antibody, specific to a carcinoembryonic antigen, a chimeric mononuclear T-cell receptor, a vector, a host cell and a method of diagnostics or treatment of diseases, characterised by the presence of antigens, capable of binding with the chimeric receptor. Described is a genetic construction, coding chimeric monomolecular T-cell receptors, in which an effector fragment of the T-cell receptor is combined with an antigen-recognising part, which represents variable fragments of two different antibodies to the carcinoembryonic antigen (CEA).
EFFECT: claimed inventions can be used in T-cell cancer therapy.
7 cl, 4 dwg, 3 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| MONOMOLECULAR CHEMERIC T-CELLULAR RECEPTOR TO CANCER-EMBRYONIC ANTIGEN | 2015 |
|
RU2650858C2 |
| MONOMOLECULAR CHIMERIC T-CELLULAR RECEPTOR TO CANCER-EMBRYONIC ANTIGEN | 2015 |
|
RU2652955C1 |
| MONOMOLECULAR CHIMERIC T-CELL RECEPTOR TO CANCER ANTIGEN CA125 | 2018 |
|
RU2747095C2 |
| NK CELL LINE EXPRESSING PSMA-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND SECRETING CD47/SIRPA INTERACTION BLOCKER | 2020 |
|
RU2757353C1 |
| GENETIC CONSTRUCT CODING STRUCTURE OF T-CELL CHIMERIC RECEPTOR BASED ON SINGLE-CHAIN VHH ANTIBODIES SPECIFIC TO TUMOUR RECEPTOR CD47 FOR THE TARGETED IMMUNOTHERAPY OF MALIGNANT GROWTHS | 2017 |
|
RU2707535C2 |
| PSCA-CAR-YT CELL LINE HAVING SURFACE EXPRESSION OF CHIMERIC ANTIGEN RECEPTORS AND EXHIBITING CYTOTOXIC ACTIVITY ON PSCA-POSITIVE HUMAN CANCER CELLS | 2018 |
|
RU2712901C1 |
| CHIMERIC ANTIGEN RECEPTOR WITH COSTIMULATORY DOMAIN 4-1BB | 2020 |
|
RU2830540C2 |
| MODIFIED NATURAL KILLER CELLS AND NATURAL KILLER CELL LINES WITH INCREASED CYTOTOXICITY | 2016 |
|
RU2772348C2 |
| RECOMBINANT CYTO-CAR-YT-LACT CELL LINE EXHIBITING HIGH CYTOTOXIC ACTIVITY WITH RESPECT TO PSCA-POSITIVE HUMAN CANCER CELLS | 2019 |
|
RU2724431C1 |
| CELL THERAPY BASED ON IMPROVED NATURAL KILLER CELLS | 2017 |
|
RU2776890C2 |
